Neuropeptide Y clinical trials
How each study uses Neuropeptide Y is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Neuropeptide Y studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Dennis Charney (1) · James Murrough (1) · University of Texas Southwestern Medical Center (1) · New York Medical College (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Neuropeptide Y.
- Dec 2026Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)Early Phase 1 · University of Texas Southwestern Medical Center
Studies
Open first, then newest update. How each study uses Neuropeptide Y is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)RecruitingEarly Phase 1University of Texas Southwestern Medical CenterNCT04838678Written as Neuropeptide Y
- Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderStatus unknownPhase 1/2New York Medical CollegeNCT04071600Written as Neuropeptide Y
- Intranasal Administration of Neuropeptide Y in Healthy Male VolunteersCompletedPhase 2Dennis CharneyNCT00748956Written as Low dose NPY
- A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)CompletedPhase 1James MurroughNCT01533519Written as Neuropeptide Y
Codes
What other systems call Neuropeptide Y · ClinicalTrials.gg INT007882
- Wikidata Q414992Neuropeptide YOne source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q414992 | Neuropeptide Y | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.